This study will be conducted in four districts of Mityana, Masaka, Hoima and Kalangala for a period of six years. According to Dr. Flavia Matovu Kiweewa, a Researcher based at the Makerere University -Johns Hopkins University Research Collaboration, participants will be receiving an injection every after six months.
Researchers will in December enroll first participants in a
clinical trial in which they are testing the effectiveness of a new HIV drug
Lenacapavir in protecting people from getting infected.
This study will be conducted in four districts of Mityana,
Masaka, Hoima and Kalangala for a period of six years. According to Dr. Flavia
Matovu Kiweewa, a Researcher based at the Makerere University -Johns Hopkins
University Research Collaboration, participants will be receiving an
injection every after six months.
///Cue in: “Lenacapavir is an …………
Cue out: ………… never been on ART”. //
In addition to the injection which has also been trailed as
treatment among the HIV positive, volunteers who are young women and adolescent
girls will have to take a daily pill of an equally new drug Descovy which was
only approved for use internationally as a Pre Exposure Prophylaxis -PrEP recently.
//Cue in:” We have the injection …….
Cue out: ………. In those areas”. //
In Masaka, she says they already have done an initiating
survey to establish the HIV incidence levels whose results will be released
officially in November but they saw high prevalence that she partly attributes
to COVID-19 pandemic interruptions.
//Cue in:” We’ve gone ahead ………..
Cue out: ……… really getting HIV”//
If found effective, the researcher says it will be a great
addition to the HIV prevention tools as there is already oral PrEP and the
vaginal ring approved for use in women.
She says with oral PrEP, they are finding challenges with uptake
including consistent use and stigma especially that the same drugs are used and
at times picked from similar health facilities like for the HIV positive.
//Cue in: “We have few ……..
Cue out: ……… gaps with oral PrEP”. //
However, while a number of prevention methods have been
tried here before being rolled out elsewhere, Uganda still lags in terms of
adoption of even the earliest oral PrEP which was approved for use more than
five years ago.
Dr. Herbert Kadama, the Coordinator of PrEP in the Ministry
of Health says they are only providing the drugs through donor funding even as
they estimate use of PrEP can help them avert up to 9000 new infections. The country recorded 38,000 new infections in
According to Kadama, about 150,000 people have enrolled for
PrEP at the 260 sites designated throughout the country having been adopted for
use in 2016. He says most of their clients are sex workers. But, they are not consistently using their
//Cue in: “We have a screening ………
Cue out: ………. Not virally suppressed”..//
Meanwhile, the criteria used for enrolling people into PrEP
include anyone who has used Post Exposure Prophylaxis (PEP) for more than three
times, those with multiple sex partners and if one has been treating recurrent sexually
transmitted infections in a year.
Researchers say PrEP is the best option for Uganda where a
huge number of young women and girls are still getting infected and yet many
cannot negotiate consistent condom use.